The IL11 Knockout SK-HEP-1 Polyclonal Cells represent a genetically disrupted population of SK-HEP-1 liver adenocarcinoma cells generated by CRISPR/Cas9-mediated disruption of the IL11 gene. This polyclonal knockout product provides a heterogeneous pool of edited cells, each carrying distinct loss-of-function mutations in IL11, enabling robust modeling of IL-11 signaling deficiency without single-cell cloning. The product format allows researchers to interrogate the functional consequences of IL-11 ablation in a cellular context that preserves the phenotypic diversity inherent to the parental tumor line.
The SK-HEP-1 cell line, originally isolated from ascitic fluid of a patient with liver adenocarcinoma, is an established adherent epithelial model for hepatocellular carcinoma. These cells exhibit morphological and molecular features consistent with malignant hepatocytes and are widely employed in studies of liver cancer biology, metastasis, and therapeutic responses. The adherent growth characteristics facilitate a broad range of in vitro assays, and the polyclonal knockout format maintains the heterogeneity of the tumor-derived population while eliminating functional IL-11 expression.
Interleukin-11 (IL-11) is a pleiotropic cytokine that transduces signals through a heterodimeric receptor complex composed of IL11RA and the gp130 (IL6ST) co-receptor. Ligand binding activates receptor-associated JAK1 and JAK2 kinases, which phosphorylate and activate the transcription factors STAT3 and STAT1. Activated STAT dimers translocate to the nucleus to modulate expression of genes such as BCL2, SOCS3, and SNAI1, thereby regulating cell survival, proliferation, and epithelial-mesenchymal transition. IL-11 signaling additionally engages the MAPK/ERK and PI3K/AKT cascades, and is transcriptionally induced by upstream factors including TGF-beta, IL-1, TNF-alpha, and hypoxia, with STAT3 participating in feed-forward amplification.
In the context of SK-HEP-1 hepatocellular carcinoma cells, IL-11 signaling contributes to tumor growth, invasion, and apoptotic resistance, reflecting its described roles in hepatocellular carcinoma progression and liver fibrosis. Disruption of IL11 in this polyclonal model abrogates ligand-dependent activation of downstream effectors, allowing dissection of IL-11-specific contributions to malignant phenotypes. The model is particularly relevant for examining the mechanistic interplay between TGF-beta and IL-11 pathways, as TGF-beta is a potent inducer of IL-11 in hepatic stellate cells and tumor microenvironments.
Researchers can employ this knockout cell population in diverse experimental settings, including hepatocellular carcinoma studies, liver fibrosis modeling, and validation of therapeutic targets. Compatible assays include Western blotting for phospho-STAT3 and total STAT3, RT-qPCR to confirm IL11 mRNA disruption, cell proliferation and viability assays, Transwell migration and invasion assays, and STAT3 luciferase reporter assays. Co-immunoprecipitation of IL11RA and gp130 can be used to assess receptor complex integrity in the absence of the ligand. For additional technical details or to discuss custom applications, please contact Ascent Research.
